All Other Miscellaneous Ambulatory Health Care Services (NAICS 621999)

An investor's primer — U.S. industry, for public-market and private investors

1. Overview

NAICS (North American Industry Classification System) code 621999 is the catch-all bucket for outpatient ("ambulatory," meaning the patient is treated without an overnight hospital stay) health services that do not fit any other named category. In plain terms it is a residual grab-bag: workplace drug testing, community and biometric health screenings, mobile physical exams, hearing tests, physical-fitness evaluations, smoking-cessation programs, in-home health assessments, remote pacemaker and cardiac monitoring, and medical case management.[1][2] It is not a single business — it is a dozen loosely related niches that federal statisticians file together because none is large enough to earn its own code.

Why it matters as an investment area: parts of this bucket are attractive, recurring-fee, capital-light health services with structural tailwinds (an aging population, the shift of care out of hospitals, employer testing mandates). But the industry as officially measured is small and extremely fragmented — the four largest firms hold only about 21% of revenue.[4] There is almost no way to own "621999" as a clean theme. The realistic opportunity is either exposure to one specific niche (remote cardiac monitoring, medical case management, occupational health) or private ownership of a local screening, testing, or care-management business — which is where the bulk of this fragmented industry actually lives.

The governing principle for any investor here is to underwrite the specific service line, payer, customer, and geography — not the NAICS code. Public-market investors mostly gain exposure through larger companies that run a screening, monitoring, occupational-health, or care-management business as one segment. Private investors can buy operating companies outright, fund growth, or build regional platforms through mergers and acquisitions (M&A).

2. What it is and how it's structured

Scope — what's inside 621999. The Census Bureau's illustrative examples and index entries include:[1][2]

• Workplace/employer drug testing — collection sites and program administration (the analytical lab work itself is often a separate business; see exclusions below).
• Health screening services performed outside a doctor's office — biometric screenings, blood-pressure and vascular screening, community wellness events.
• Mobile and in-home physical examinations and health assessments (including risk-assessment visits for health plans).
• Hearing testing (except by audiologists) and physical-fitness evaluation (except by health practitioners).
• Pacemaker and remote cardiac monitoring services.
• Smoking-cessation / stop-smoking programs.
• Medical care management and medical case management services (e.g., coordinating care for workers'-compensation or complex cases).

Services are delivered at employer sites, in mobile units, in homes, in small clinics, or remotely, and can be paid for by employers, insurers, workers'-compensation programs, health plans, government agencies, health systems, or consumers.[3]

What it EXCLUDES (and where those activities go). This is the key to reading the code — most healthcare you can think of is filed elsewhere:[1][2]

• Offices of physicians and dentists → NAICS 6211 / 6212.
• Offices of other health practitioners (audiologists, optometrists, therapists) → NAICS 6213.
• Outpatient care centers, including family-planning and dialysis centers → NAICS 6214.
• Medical and diagnostic laboratories — including the labs that actually analyze drug-test specimens and blood → NAICS 6215. This matters: a workplace drug screen is typically split between a 621999 collection/administration business and a 6215 testing lab. (It also means Quest Diagnostics and Labcorp are useful comparables but their core lab business sits outside 621999.)
• Home health care → NAICS 6216.
• Ambulance services → NAICS 621910.
• Blood and organ banks → NAICS 621991.

So 621999 is literally "other ambulatory health, not classified above."[1]

Ownership mix. The activity is predominantly small, privately held, and for-profit — many operators are single-site businesses or sole proprietors. A minority sits inside larger corporations (diagnostics majors, medical-device makers, occupational-health chains, health-plan-services companies) that run these services as a segment, and private-equity ownership is common in the consolidating niches. The supplied federal statistics do not break the industry into a public/private, nonprofit/government, or employer/nonemployer split, so no primer should claim a precise ownership share — only the qualitative pattern above.

3. How big it is

Federal statistics on the employer portion of the industry (U.S.). Payroll, employment, and establishment counts are 2023 (County Business Patterns); receipts, firm counts, and concentration are 2022 (Economic Census):

That works out to average receipts of roughly $3.5 million per firm and average pay near $69,000 per employee — a small, service-heavy, low-concentration industry.[4][5] The HHI (a standard concentration gauge that sums the squared market shares of all firms) is just 167.8; U.S. antitrust agencies treat a market above 1,800 as "highly concentrated," so this industry sits an order of magnitude below that line — one of the most fragmented you will find.[4][40]

The undercount caveat — read this before trusting the size figures. Two things make 621999 larger and messier than the table suggests. First, the federal employer counts above exclude nonemployer businesses (sole proprietors with no payroll), businesses without an employer identification number, and most government establishments; County Business Patterns and the Economic Census are both employer-business frames.[7][8] Commercial marketing databases that sweep in nonemployers count tens of thousands of "companies" in this code versus the ~7,270 employer firms in the Economic Census.[4][7] Second, and more important, this is a residual category: many of the underlying activities (drug-test analysis, screenings run by hospitals or physician groups, cardiac monitoring billed by cardiology practices, in-home assessments billed by health plans) are captured under other NAICS codes — labs, physician offices, hospitals, device makers. The true economic footprint of "miscellaneous ambulatory services" is therefore spread across several industries; the $25.4 billion figure counts only businesses whose primary activity lands here. Treat it as a floor for a set of niches, not a clean market size. The supplied data do not quantify the gap, and no suppressed value is used anywhere in this primer.

4. The investable universe

There is no clean public pure-play that reports a separate 621999 revenue line. The closest listed exposures are companies whose core business is one of the named activities — remote cardiac monitoring, medical case management, occupational health, or health assessments — though index and data providers often classify them under medical devices, laboratory services, or managed care rather than this code. Treat the tickers below as exposure to slices of the bucket, not to the bucket itself.

Public companies

Large diversified owners (these services are a small segment)

Employer drug screening and biometric screening run through the diagnostics majors — Quest Diagnostics (DGX), which performs roughly 10 million drug tests a year, and Labcorp (LH) — although the lab work is classified under NAICS 6215.[14] Remote cardiac monitoring has consolidated into big device and health-tech companies: Philips (bought BioTelemetry in 2021) and Boston Scientific (BSX) (bought Preventice in 2021), alongside Abbott (ABT) and Medtronic (MDT) in cardiac diagnostics.[15]

Representative private / PE-backed owners and operators

This is where most of the industry sits. It is a representative list, not a ranking — the federal data do not identify company-level market shares:

• Life Line Screening — direct-to-consumer community vascular and health screening; private-equity backed (Kinderhook Industries).[16]
• DISA Global Solutions — large third-party administrator (TPA) for workplace drug and health testing programs; private.[17]
• Premise Health (OMERS Private Equity) — employer-sponsored onsite, near-site, occupational-health, wellness, and primary-care services.[22]
• Matrix Medical Network (Frazier Healthcare Partners) — home-based health assessments, preventive care, diagnostic testing, and care management.[23]
• Enlyte, including Genex (Stone Point Capital) — workers'-compensation case management, medical cost containment, and utilization review.[24]
• Examinetics (Coalesce Capital) — occupational-health screening, compliance testing, and workplace safety.[25]
• ExamWorks — independent medical examinations, peer reviews, bill reviews, and Medicare-compliance services.[26]
• Independent and franchised collection-site networks and specialty labs such as Cordant Health Solutions and Omega Laboratories.[14]

Bottom line: no dedicated exchange-traded fund (ETF) or clean public proxy tracks this NAICS. Liquid public exposure realistically means a focused name (iRhythm for monitoring, CorVel for case management), an occupational-health name (Concentra), or a small slice of a diversified diagnostics, device, or managed-care major.

5. How the money works

These are transactional, service-fee businesses; revenue is fundamentally volume × price per test, encounter, monitoring study, or case. The models vary by who pays:

• Fee-for-service / employer-paid (drug testing, biometric screening, occupational health). Cash-like commercial pricing, competitive and somewhat commoditized on the collection/administration side. Volume tracks hiring and headcount, especially in safety-sensitive, federally regulated sectors. The differentiated margin sits in the analytical lab step and in program administration (chain-of-custody, reporting, compliance).
• Employer contracts — fixed site fees, hourly clinical coverage, or per-employee pricing for onsite and near-site clinics.
• Per-member-per-month (PMPM) — recurring payments for care management, navigation, or chronic-condition support.
• Insurance / Medicare-reimbursed (cardiac and pacemaker monitoring, some screenings and assessments). Billed to payers via CPT (Current Procedural Terminology) codes; the single most important variable is the reimbursement rate set by CMS (the Centers for Medicare & Medicaid Services) and commercial payers. A repricing of the long-term continuous-ECG codes can swing a monitoring company's revenue materially — both the upside and the central risk for iRhythm-type businesses.[9]
• Performance arrangements — shared savings, quality bonuses, or fees tied to medical-cost or return-to-work outcomes.
• Government and workers'-compensation contracts — negotiated fee schedules, per-case fees, or fixed-price arrangements.
• Consumer out-of-pocket — Life Line Screening's model: priced per screening package, marketed to older adults, collected up front; economics driven by marketing efficiency, site utilization, and package attach rates.

Cost structure and unit economics. The main cost is clinical labor — nurses, technicians, physicians, nurse practitioners, and care managers — plus facilities, mobile units, devices, lab supplies, software, credentialing, malpractice coverage, sales, and cybersecurity. The analysis/interpretation layer can be high-margin (Biotricity has reported gross margins above 80%, and iRhythm runs a high-gross-margin monitoring model),[9][12] but heavy sales-and-marketing costs to win cardiologist, employer, and payer relationships make operating margins thinner than gross margins suggest. Collection-site and mobile-screening operations are more labor- and logistics-driven.

Metrics that matter: completed encounters/tests/assessments per clinician shift; revenue per encounter or case; clinician utilization and labor cost per encounter; reimbursement rates, denial and appeal rates, and days-sales-outstanding (collection time); contract renewal and customer-retention rates; case-closure and return-to-work performance; monitoring turnaround time and device uptime; and customer/payer concentration. The supplied statistics contain no industry-wide margin, growth, reimbursement, or utilization figures — those should not be invented from aggregate receipts and payroll.

6. What drives demand

• Aging population and chronic disease — the strongest structural tailwind: more older adults means more arrhythmia detection, cardiac monitoring, preventive screening, and coordinated care outside hospitals.[36][37]
• Shift to remote and outpatient care — expanding reimbursement for remote patient monitoring and the move of diagnostics out of the hospital favor patch-based, mobile, and in-home services. iRhythm's filings illustrate how a device plus software plus clinical interpretation turns monitoring into a recurring service rather than a one-time equipment sale.[9][29]
• Employment and hiring levels — pre-employment and random drug screening scale with new hires and total workforce, so volumes are mildly cyclical with the labor market.[14]
• Regulatory testing mandates — DOT (Department of Transportation)-regulated industries (trucking, transit, aviation, rail) must test safety-sensitive workers, providing a durable floor of demand.[27]
• Cannabis liberalization (a headwind) — as more states legalize marijuana and several (California, Washington, Minnesota) bar pre-employment testing for non-psychoactive cannabis metabolites, marijuana-screening volumes and program economics are pressured — a factor in the multi-year revenue decline at hair-testing specialist Psychemedics.[13][28]
• Employer wellness and preventive-health demand — corporate biometric screening, onsite clinics, and consumer interest in early detection support the screening and occupational-health niches.[27]

Judgment: the most attractive growth niches are services with recurring payer or employer contracts, measurable outcomes, and standardized workflows. One-off cash screening tends to grow more slowly and has weaker retention and pricing power.

7. Regulation

The code does not determine the regulatory burden — the specific service does. The main layers:

• Workplace drug testing. HHS/SAMHSA (the Substance Abuse and Mental Health Services Administration) sets the Mandatory Guidelines for federal workplace testing — which drugs, what cutoffs, collection procedures — and DOT rules (49 CFR Part 40) govern safety-sensitive transportation testing. Forensic, court-defensible testing must run through a SAMHSA-certified lab, a higher bar than the CLIA certification used for clinical patient testing.[27]
• Laboratory testing. CMS regulates human lab testing through the CLIA (Clinical Laboratory Improvement Amendments), including tests performed outside traditional labs; screening operations also face state facility licensing.[32]
• Medical devices. Cardiac monitors and biosensors typically need FDA (Food and Drug Administration) clearance, usually a 510(k); Biotricity's and iRhythm's patches cleared this way.[30][33]
• Reimbursement. CMS pricing and CPT coding set what payers pay for monitoring and some screenings — a de facto regulatory lever on revenue.[9]
• Billing, referrals, and coding. The Anti-Kickback Statute (AKS), the False Claims Act (FCA), and the physician self-referral (Stark) law create serious exposure wherever federal healthcare payments, referrals, or diagnosis coding are involved.[34] The risk is not theoretical: in June 2026 the Department of Justice announced a $56.5 million settlement with Matrix Medical Network and HealthFair over allegedly invalid Medicare Advantage diagnosis coding from in-home assessments — a direct illustration of the audit and FCA risk attached to health-assessment and risk-adjustment work.[38]
• Privacy and employment law. HIPAA (the Health Insurance Portability and Accountability Act) governs protected health information (with carve-outs for DOT testing disclosures);[31] the ADA (Americans with Disabilities Act), GINA (Genetic Information Nondiscrimination Act), and EEOC (Equal Employment Opportunity Commission) rules constrain employer medical exams and wellness screenings;[35] and a growing patchwork of state cannabis and off-duty-use laws limits what employers may test for.[28]
• State oversight. Professional licensing, scope-of-practice rules, clinic requirements, telehealth rules, and corporate-practice-of-medicine restrictions vary by state.

8. Competitive dynamics and consolidation

The industry is structurally fragmented (HHI 167.8; top four firms ~21% of revenue).[4] The U.S. antitrust agencies treat markets above an HHI of 1,800 as highly concentrated, so nationally this industry is nowhere near a competition concern.[40] But that headline hides two very different worlds, and a low national HHI does not rule out strong local concentration in occupational health, medical exams, cardiac monitoring, or case management:

• A long tail of tiny operators — collection sites, small screening outfits, single-clinic occupational-health businesses — where competition is local and price-driven and switching costs are low.
• Pockets where scale and credentials create real moats — national lab and monitoring networks with large device fleets plus AI-driven interpretation and hard-won CMS/payer reimbursement, and TPAs with employer contracts and chain-of-custody credibility.

Where scale helps: centralized scheduling, billing, and credentialing; better payer contracts and referral networks; higher utilization of mobile teams and clinical staff; shared software, compliance, and data infrastructure; and cross-selling across employers, insurers, and health plans.

Consolidation is active in the higher-value niches. Strategic acquirers rolled up cardiac monitoring (Philips/BioTelemetry and Boston Scientific/Preventice, both 2021), and private equity is consolidating occupational health (Premise Health, Examinetics), drug-testing administration (DISA), workers'-comp case management (Enlyte/Genex), in-home assessments (Matrix Medical), and consumer screening (Life Line Screening).[15][22][23][24][25] Barriers that protect the consolidators: SAMHSA/CLIA/FDA credentials, payer contracts and reimbursement track record, forensic chain-of-custody reliability, and distribution relationships with employers and cardiologists. Note that federal agencies (FTC, DOJ, HHS) have specifically scrutinized healthcare roll-ups, vertical integration, and their effects on quality and cost.[39]

Judgment: consolidation should continue in the fragmented, contract-driven subsegments, but roll-ups create value only when density, clinical quality, compliance, and integration improve together.

9. Risks

• Reimbursement cuts. For the monitoring niche, a CMS/CPT repricing can compress revenue quickly; heavy Medicare-rate dependence is the dominant risk for iRhythm-type names. More broadly, payers can cut fees, tighten authorization, or shift work to lower-cost channels.[9]
• Cannabis-driven demand erosion. Loosening marijuana rules and state testing bans structurally shrink parts of the drug-testing market (illustrated by Psychemedics' declining revenue and OTC delisting).[13][28]
• Labor shortages. Scarcity of nurses, physicians, technicians, and care managers can cap capacity and compress margins.
• Customer/payer concentration and collections risk. Losing one employer, insurer, health plan, or referral source can materially reduce volume; insurance-billed lines carry denial and long-DSO risk.
• Clinical liability. Screening errors, missed diagnoses, poor care coordination, chain-of-custody disputes, or faulty monitoring can create lawsuits and reputational damage.
• Compliance and coding risk. HIPAA breaches, CLIA failures, improper referrals, and inaccurate diagnosis coding can trigger FCA penalties and contract loss (see the 2026 Matrix/HealthFair settlement).[38]
• Technology and device risk. Cyberattacks, software errors, AI-model failures, and FDA actions or device recalls can interrupt service.
• Cyclicality. Less cyclical than elective procedures, but demand can soften with employment, workers'-comp claims, employer-benefit cuts, or government-budget pressure.
• M&A/leverage risk. Debt-funded roll-ups magnify both returns and the cost of integration, retention, and regulatory failures.
• "Residual bucket" measurement risk. Because the category is a statistical catch-all whose activity spills into labs, physician offices, and hospitals, it is hard to isolate, size, or benchmark as an investment theme, and reclassification can move activity in or out.

10. How to invest, and the outlook

Public routes

Liquid public exposure is narrow and always partial:

• Focused exposure — iRhythm (IRTC) for remote cardiac monitoring (understand it as a reimbursement-sensitive med-tech growth stock, not a diversified industry play) and CorVel (CRVL) for medical case management and workers'-comp cost management.[9][10][11][18]
• Occupational health — Concentra (CON), though much of its revenue is physician/clinic activity outside 621999.[20]
• Broader / embedded exposure — CVS Health (CVS) via Signify Health's in-home evaluations and Evolent Health (EVH) for care and utilization management, plus the diagnostics majors (Quest / DGX, Labcorp / LH) and device makers (Boston Scientific / BSX, Abbott / ABT, Medtronic / MDT, Philips), where these services are a small segment.[14][15][19][21]
• Micro-cap / speculative — Biotricity (BTCY) and Psychemedics (PMDI) are illiquid and highly speculative.[12][13]

There is no dedicated ETF for this NAICS. The correct approach: identify the relevant segment or subsidiary; estimate what share of revenue truly resembles 621999; track payer mix, reimbursement, labor productivity, renewals, and cash flow; avoid applying a pure-play valuation to a diversified company; and treat clinical quality, regulatory compliance, and customer concentration as investment variables, not footnotes.

Private routes — where most of the industry actually is

The fragmented, mostly-private structure and the SBA (Small Business Administration) size standard of $20.5 million in receipts (so most operators qualify as "small") make this fertile ground for private ownership:[6] private-equity roll-ups in occupational health, drug-testing administration, case management, and screening; buy-and-build platforms and growth capital for mobile or remote delivery; and acquiring local collection-site, mobile-screening, or occupational-health businesses (including via search fund or SBA-backed small-business acquisition). Due diligence should focus on referral arrangements, coding practices, clinician retention, revenue by payer and customer, denial rates, contract-termination rights, data security, licensing, malpractice history, and acquisition-integration track record.

Outlook — judgment

Base case: steady underlying demand with continued fragmentation. Aging, chronic disease, employer-sponsored care, remote monitoring, and payer pressure to control avoidable costs should support the better operators. The cardiac and remote-monitoring slice looks structurally favored — aging demographics, expanding remote-monitoring reimbursement, and AI-driven interpretation that improves both accuracy and margins — provided reimbursement rates hold. The drug-testing slice looks flat-to-soft as cannabis liberalization erodes marijuana screening, though DOT-mandated testing provides a durable floor. Case management, occupational health, and health assessments should grow with the shift to recurring, technology-enabled contracts and measurable outcomes — the upside case — while the downside case is reimbursement pressure combined with labor shortages, regulatory enforcement, or overleveraged consolidation.

Net: 621999 is investable as a collection of specialized healthcare-service niches, not as a single market with one demand curve, one margin profile, or one obvious public-market vehicle. It is a bucket to mine niche-by-niche, not to buy wholesale.

---

Sources

1. U.S. Census Bureau, 2022 NAICS Definition — 621999 All Other Miscellaneous Ambulatory Health Care Services, 2022. https://www.census.gov/naics/?input=621999&year=2022&details=621999
2. NAICS Association, 621999 — All Other Miscellaneous Ambulatory Health Care Services (definition, index entries, cross-references), 2024. https://www.naics.com/naics-code-description/?code=621999
3. U.S. Census Bureau, 2022 Health Care and Social Assistance Industry Questionnaire (NAICS 62199), 2022. https://bhs.econ.census.gov/ombpdfs2022/export/2022_HC-62199_su.pdf
4. U.S. Census Bureau, 2022 Economic Census — Concentration of Largest Firms / Selected Statistics, NAICS 621999 (firms 7,270; receipts $25.413B; CR4 21.4%, CR8 28.7%, CR20 38.8%, CR50 50.4%; HHI 167.8), 2025. https://data.census.gov/table/ECNSIZE2022.EC2200SIZECONCEN
5. U.S. Census Bureau, County Business Patterns, NAICS 621999 (9,527 establishments; 117,066 employees; $8.128B annual payroll; $2.064B Q1 payroll), 2023. https://www.census.gov/programs-surveys/cbp.html
6. U.S. Small Business Administration, Table of Size Standards — NAICS 621999 ($20.5M average annual receipts), 2023. https://www.sba.gov/document/support-table-size-standards
7. IBISWorld, NAICS 621999 — All Other Miscellaneous Ambulatory Health Care Services (industry profile / establishment counts), 2024. https://www.ibisworld.com/classifications/naics/621999/all-other-miscellaneous-ambulatory-health-care-services/
8. U.S. Census Bureau, Frequently Asked Questions: About the Economic Census (nonemployer and government-establishment exclusions), 2022. https://www.census.gov/programs-surveys/economic-census/year/2022/about/faq/faq-general.html
9. iRhythm Technologies, Annual Report on Form 10-K and quarterly results (2025 revenue ~$720–730M; long-term ECG reimbursement/CPT commentary), 2025/2026. https://www.sec.gov/Archives/edgar/data/1388658/000138865826000011/irtc-20251231.htm
10. iRhythm Technologies, Fourth Quarter 2025 / Full-Year Results and 2026 Guidance (Form 8-K, revenue ~$875–885M guided), 2026. https://www.sec.gov/Archives/edgar/data/1388658/000138865826000009/irtcq42025ex991pressrelease.htm
11. companiesmarketcap.com, iRhythm Technologies (IRTC) market capitalization (~$3.8B, mid-2026), 2026. https://companiesmarketcap.com/irhythm/marketcap/
12. Biotricity Inc., Q3 Fiscal 2026 Results (revenue ~$4M/quarter, ~$15M TTM; ~81.5% gross margin), 2026. https://biotricity.com/2026/02/11/biotricity-delivers-strong-q3-fiscal-2026-performance-growing-revenue-momentum-and-expanding-ebitda/
13. Psychemedics Corporation, Form 10-K FY2024 and results (2024 revenue $19.7M, −11% y/y; OTC delisting), 2025. https://www.sec.gov/Archives/edgar/data/806517/000117184325001658/pmd20241231_10k.htm
14. GlobeNewswire / Research and Markets, U.S. Employer and Workplace Drug Testing Market Report 2024 (players: First Advantage, Labcorp, Quest Diagnostics, Cordant, Omega, Psychemedics; Quest ~10M tests/year), 2024. https://www.globenewswire.com/news-release/2024/10/15/2963369/28124/en/U-S-Employer-and-Workplace-Drug-Testing-Market-Report-2024.html
15. Koninklijke Philips N.V. / Boston Scientific, Philips completes acquisition of BioTelemetry; Boston Scientific acquisition of Preventice Solutions (both 2021), 2021. https://www.philips.com/a-w/about/news/archive/corpcomms/news/press/2021/20210208-philips-completes-the-acquisition-of-biotelemetry.html
16. Life Line Screening / Kinderhook Industries, Community preventive screening; private-equity ownership, 2024. https://en.wikipedia.org/wiki/Life_Line_Screening
17. DISA Global Solutions, Workplace drug & health testing / third-party administration (company overview), 2026. https://disa.com/
18. CorVel Corporation, Annual Report on Form 10-K, 2025. https://www.sec.gov/Archives/edgar/data/874866/000095017025076999/crvl-20250331.htm
19. CVS Health, Annual Report on Form 10-K (Signify Health in-home evaluations), 2023/2024. https://www.sec.gov/Archives/edgar/data/64803/000006480324000007/cvs-20231231.htm
20. Concentra Group Holdings Parent, Annual Report on Form 10-K, 2025/2026. https://ir.concentra.com/sec-filings/all-sec-filings/content/0002014596-26-000029/cghp-20251231.htm
21. Evolent Health, Annual Report on Form 10-K, 2025/2026. https://www.sec.gov/Archives/edgar/data/1628908/000162890826000015/evh-20251231.htm
22. OMERS Private Equity, Premise Health, 2026. https://omersprivateequity.com/investments/premise-health
23. Frazier Healthcare Partners, Portfolio: Matrix Medical Network, 2026. https://www.frazierhealthcare.com/portfolio/
24. Stone Point Capital, Enlyte (including Genex), 2026. https://www.stonepoint.com/company/enlyte/
25. Coalesce Capital, Examinetics portfolio company, 2025. https://coalescecap.com/news/examinetics-a-coalesce-capital-portfolio-company-adds-to-offering-with-acquisition-of-safety-consulting-firms-pekron-consulting-and-rpf-environmental/
26. ExamWorks, About ExamWorks, 2025. https://www.examworks.com/about/about-examworks
27. U.S. Substance Abuse and Mental Health Services Administration (SAMHSA), Workplace Drug Testing Resources; Mandatory Guidelines and DOT 49 CFR Part 40; SAMHSA- vs CLIA-certified labs, 2025. https://www.samhsa.gov/substance-use/drug-free-workplace/drug-testing-resources
28. NORML / Jackson Lewis, State pre-employment marijuana testing restrictions (California AB 2188; Washington SB 5123; Minnesota), 2024. https://norml.org/blog/2024/01/02/washington-new-state-law-takes-effect-barring-pre-employment-marijuana-testing-for-most-employees/
29. Mordor Intelligence, Mobile Cardiac Telemetry Systems Market — size and growth outlook (aging population, remote monitoring reimbursement), 2026. https://www.mordorintelligence.com/industry-reports/mobile-cardiac-telemetry-systems-market
30. Biotricity Inc., FDA 510(k) clearance of Biotres cardiac monitor (device-regulation example), 2022. https://biotricity.com/
31. U.S. Department of Health and Human Services, HIPAA — Covered Entities and Business Associates, 2024. https://www.hhs.gov/hipaa/for-professionals/covered-entities/index.html
32. Centers for Medicare & Medicaid Services, Clinical Laboratory Improvement Amendments (CLIA), 2026. https://www.cms.gov/medicare/quality/clinical-laboratory-improvement-amendments
33. U.S. Food and Drug Administration, Device Approvals and Clearances, 2026. https://www.fda.gov/medical-devices/products-and-medical-procedures/device-approvals-and-clearances
34. U.S. Department of Health and Human Services, Office of Inspector General, Fraud & Abuse Laws (Anti-Kickback Statute, False Claims Act, physician self-referral/Stark), 2026. https://oig.hhs.gov/compliance/physician-education/fraud-abuse-laws/
35. U.S. Equal Employment Opportunity Commission, Final Rules on Employer Wellness Programs (ADA and GINA), 2016. https://www.eeoc.gov/newsroom/eeoc-issues-final-rules-employer-wellness-programs
36. U.S. Census Bureau, Population Projections for the Nation (aging), 2023. https://www.census.gov/newsroom/press-releases/2023/population-projections.html
37. Centers for Disease Control and Prevention, About Chronic Diseases, 2026. https://www.cdc.gov/chronic-disease/about/index.html
38. U.S. Department of Justice, Matrix, HealthFair, and HealthFair Founder Agree to Pay $56.5M to Resolve False Claims Act Allegations (Medicare Advantage risk-adjustment coding), 2026. https://www.justice.gov/opa/pr/matrix-healthfair-and-healthfair-founder-agree-pay-565m-resolve-false-claims-act-allegations
39. Federal Trade Commission / DOJ / HHS, Cross-Government Inquiry on Corporate Control (including private equity) in Health Care, 2024. https://www.ftc.gov/news-events/news/press-releases/2024/03/federal-trade-commission-department-justice-department-health-and-human-services-launch-cross-government
40. U.S. Department of Justice & Federal Trade Commission, 2023 Merger Guidelines, Guideline 1 (HHI thresholds; markets above 1,800 treated as highly concentrated), 2023. https://www.justice.gov/atr/merger-guidelines/applying-merger-guidelines/guideline-1